Revenue (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:

	Year ended December 31,
	2021				2020				2019
Product line	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Infusion Consumables	$	555,189	42	%	$	473,740	37	%	$	477,611	37	%
Infusion Systems	352,321		27	%	359,691		28	%	328,282		26	%
IV Solutions	359,477		27	%	388,971		31	%	414,971		33	%
Critical Care	49,321		4	%	48,602		4	%	45,344		4	%
Total Revenues	$	1,316,308	100	%	$	1,271,004	100	%	$	1,266,208	100	%

We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.    

The following table represents our revenues disaggregated by geography (in thousands):

	Year ended December 31,
Geography	2021		2020		2019
Europe, the Middle East and Africa	$	147,488	$	132,763	$	130,530
Other Foreign	227,011		227,614		212,336
Total Foreign	374,499		360,377		342,866
United States	941,809		910,627		923,342
Total Revenues	$	1,316,308	$	1,271,004	$	1,266,208

Domestic sales accounted for 72%, 72% and 73% of total revenue in 2021, 2020 and 2019, respectively. International sales accounted for 28%, 28% and 27% of total revenue in 2021, 2020 and 2019, respectively.

Contract with Customer, Asset and Liability [Table Text Block]

Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2021 and 2020, (in thousands):

	Contract Liabilities
Beginning balance, January 1, 2020	$	(4,855)
Equipment revenue recognized	14,408
Equipment revenue deferred due to implementation	(14,341)
Software revenue recognized	5,721
Software revenue deferred due to implementation	(7,363)
Ending balance, December 31, 2020	$	(6,430)
Equipment revenue recognized	10,048
Equipment revenue deferred due to implementation	(13,725)
Software revenue recognized	7,261
Software revenue deferred due to implementation	(4,615)
Ending balance, December 31, 2021	$	(7,461)